Related Experiment Video
Updated: Sep 4, 2025

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
[Effect of Danlou Tablets on alleviating hepatic adipogenesis, inflammatory response, and insulin resistance in db/db
Ya-Fen Pang1, Ming Huang2, Lin Li2
1Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
Abstract:
This study explored the effect and potential mechanism of Danlou Tablets(DLT) on insulin resistance in db/db mice with type 2 diabetic mellitus(T2 DM). The db/db male mice were randomly assigned into model control(MC) group, metformin(MET, tablet, 100 mg·kg~(-1)) group, and DLT(1 g·kg~(-1)) group, and C57 BL/6 J mice were taken as normal control(NC) group. The mice in the MET group and DLT group were given corresponding drugs by gavage once a day for 16 weeks. The fasting blood glucose, glucose tolerance, and insulin tolerance were measured to evaluate the effect of DLT on blood glucose and insulin resistance in diabetic mice. The serum free fatty acid, triacylglycerol, and total cholesterol levels were determined to evaluate the effect of DLT on blood lipids in diabetic mice. The liver index and perirenal fat index were calculated to measure the effect of DLT on lipid accumulation in non-adipose tissue and adipose tissue. Western blot was performed to determine the protein levels of insulin receptor-β(IRβ), phospho-IRβ(p-IRβ), phosphatidylinositol 3-kinase(PI3 K), and insulin receptor substrate-1(IRS-1) involved in IRS-1/PI3 K/Akt signaling pathway in the livers of mice to reveal the mechanism of DLT in alleviating insulin resistance in diabetic mice. The protein levels of sterol regulatory element binding protein-1(SREBP-1) and the mRNA levels of sterol regulatory element binding protein-1 c(SREBP-1 c), fatty acid synthase(FAS), acetyl-CoA carboxylase(ACC), diacylglycerol acyltransferase-1(Dgat1), and diacylglycerol acyltransferase-2(Dgat2) involved in the SREBP-1/FAS signaling pathway were detected to evaluate the effect of DLT on lipid metabolism in diabetic mice. Real-time quantitative PCR was employed to determine the mRNA levels of galectin-3(Gal-3), interleukin-6(IL-6), and monocyte chemoattractant protein-1(MCP-1) in mouse liver to evaluate the effect of DLT on inflammatory response in diabetic mice. The results showed that DLT significantly reduced the blood glucose and lipid levels and alleviated the insulin resistance in diabetic mice. Compared with the MC group, DLT significantly up-regulated the protein levels of p-IRβ, PI3 K, and IRS-1(P<0.05 or P<0.01), and down-regulated the protein level of SREBP-1 in liver tissues of diabetic mice(P<0.05). DLT lowered the mRNA levels of SREBP-1 c, FAS, ACC, Dgat1, and Dgat2 related to lipid metabolism as well as those of Gal-3, IL-6, and MCP-1 associated with inflammation in the livers of diabetic mice(P<0.05 or P<0.01). The findings of this study suggest that DLT may alleviate insulin resistance in diabetic mice by regulating IRS-1/PI3 K/Akt signaling pathway and SREBP-1/FAS signaling pathway to reduce lipid production and inhibit inflammatory response.
Insights
Danlou Tablets (DLT) effectively reduced blood glucose and lipid levels in diabetic mice, improving insulin resistance. DLT works by regulating key signaling pathways involved in lipid metabolism and inflammation.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2 DM) is characterized by insulin resistance.
- Obesity and dyslipidemia are common comorbidities in T2 DM.
- Effective therapeutic strategies for T2 DM are crucial.
Purpose of the Study:
- To investigate the effects of Danlou Tablets (DLT) on insulin resistance in a mouse model of T2 DM.
- To elucidate the potential mechanisms underlying DLT's action on insulin resistance.
Main Methods:
- db/db mice were treated with DLT or metformin for 16 weeks.
- Assessed blood glucose, glucose tolerance, and insulin tolerance.
- Analyzed serum lipids, liver/fat indices, and key protein/mRNA levels in signaling pathways (IRS-1/PI3K/Akt, SREBP-1/FAS) and inflammatory markers.
Main Results:
- DLT significantly reduced blood glucose and lipid levels in diabetic mice.
- DLT treatment improved insulin sensitivity.
- DLT modulated protein and mRNA expression in the IRS-1/PI3K/Akt and SREBP-1/FAS pathways, and reduced inflammatory markers.
Conclusions:
- Danlou Tablets demonstrate therapeutic potential for type 2 diabetes.
- DLT alleviates insulin resistance by regulating lipid metabolism and inflammatory responses.
- The findings suggest DLT's efficacy is mediated through the IRS-1/PI3K/Akt and SREBP-1/FAS signaling pathways.
More Related Videos
11:03Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
Published on: September 9, 2021
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021